Supporting studies from BRAF mutant melanoma have shown that combined BRAF-MEK inhibition is effective, exhibiting synergistic growth suppression and delaying onset of resistance, and has been clinically approved for this cancer type (Flaherty et al., 2012; Larkin et al., 2014; Long et al., 2014; Dummer et al., 2018). The gene discussed is MAP2K7; the disease is cancer.